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Abstract
Background: A knowledge based planning tool has been developed and implemented for prostate VMAT
radiotherapy plans providing a target average rectum dose value based on previously achievable values for similar
rectum/PTV overlap. The purpose of this planning tool is to highlight sub-optimal clinical plans and to improve
plan quality and consistency.
Methods: A historical cohort of 97 VMAT prostate plans was interrogated using a RayStation script and used to
develop a local model for predicting optimum average rectum dose based on individual anatomy. A preliminary
validation study was performed whereby historical plans identified as “optimal” and “sub-optimal” by the local
model were replanned in a blinded study by four experienced planners and compared to the original clinical plan
to assess whether any improvement in rectum dose was observed. The predictive model was then incorporated
into a RayStation script and used as part of the clinical planning process. Planners were asked to use the script
during planning to provide a patient specific prediction for optimum average rectum dose and to optimise the
plan accordingly.
Results: Plans identified as “sub-optimal” in the validation study observed a statistically significant improvement in
average rectum dose compared to the clinical plan when replanned whereas plans that were identified as “optimal”
observed no improvement when replanned. This provided confidence that the local model can identify plans that
were suboptimal in terms of rectal sparing. Clinical implementation of the knowledge based planning tool reduced
the population-averaged mean rectum dose by 5.6Gy. There was a small but statistically significant increase in total
MU and femoral head dose and a reduction in conformity index. These did not affect the clinical acceptability of
the plans and no significant changes to other plan quality metrics were observed.
Conclusions: The knowledge-based planning tool has enabled substantial reductions in population-averaged mean
rectum dose for prostate VMAT patients. This suggests plans are improved when planners receive quantitative
feedback on plan quality against historical data.
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Background
Volume Modulated Arc Therapy (VMAT) is a popular
method of radiotherapy treatment delivery enabling high
doses of radiation to be shaped to the treatment plan
target volume (PTV) compared to conventional conformal
radiotherapy techniques. VMAT plans are inherently
complex and are typically produced in commercially
available treatment planning systems via a user-informed
inverse-planning process.
An optimum solution would deliver the full pre-
scription dose to the planning target volume whilst
delivering the lowest possible dose to surrounding
organ at risk (OAR) structures. However, the variation
in quality of a VMAT plan is ultimately influenced by
numerous factors including the number of target
structures and nearby organs-at-risk, the patient anat-
omy, planner experience and skill and the time avail-
able to produce the plan.
* Correspondence: richardpowis@nhs.net
1Worcestershire Oncology Centre, Worcestershire Acute Hospitals NHS Trust,
Worcester, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Powis et al. Radiation Oncology  (2017) 12:81 
DOI 10.1186/s13014-017-0814-z
The RayStation clinical database at Worcester contains
a record of the plan solutions produced locally for all
historical patients. For a given patient encountered in
the clinic it is likely that there already exists a patient
with a similar geometric distribution of target and OAR
structures. Furthermore, clinically acceptable plans exist
for these patients creating a knowledge base which could
be harnessed to inform users of achievable plan quality
during future plan optimisations and to potentially drive
improvements in plan quality over time.
A variety of different knowledge based planning tools
are described in the literature with varying scope and
complexity [1–8]. Moore et al. and Wu et al. independ-
ently reported that the level of achievable OAR dose
sparing is related to the geometric arrangement of the
OAR relative to the PTV [1, 2] and specifically the
extent of overlap between the OAR and PTV. Moore et
al. [1] assessed the relationship between mean OAR dose
(Dmean) and the volume of OAR overlapping a PTV
(Vovr) for a knowledge base of historical patients. They
constructed the following mathematical model for
predicting Dmean based upon the fractional OAR-PTV
overlap (Vovr/VOAR),
Dmean
DPx
¼ Aþ B 1−exp CVovr
VOAR
  
ð1Þ
where A, B and C are coefficients selected to represent
the optimal plans (in terms of OAR dose) in the know-
ledge base. The mathematical model was incorporated
into a script in the planning system which presented the
planner with a predicted value Dmean for the chosen pa-
tient. The planner was then expected to optimise the
plan in order to achieve an OAR dose less than or equal
to Dmean. This approach was found to lower the risk of
plans being produced with sub-optimal OAR average
dose and to reduce variation between planners.
Wu et al. investigated OAR and PTV overlap via the
more sophisticated concept of the overlap volume histo-
gram (OVH) [2]. The OVH was then used to identify
patients in a historical database with similar geometric
relationships between the PTV and surrounding OAR
whose dose volume histogram (DVH) were used to
guide the plan optimisation process. Appenzoller et al.
[3] built upon the work of Moore et al. to develop a
mathematical model for predicting the achievable DVH
for an OAR using the correlation between expected dose
at a point and the vicinity of that point to the PTV. The
predicted DVH curves were successfully used to guide
the plan optimisation process and to identify outlier
sub-optimal plans. Schriebmann et al. [4] proposed a
“feature-selection” search method that identified cases in
a historical database of VMAT plans with similar anat-
omy to the current patient. Once identified, the plan
configuration and DVH statistics of the similar plan
were utilised as a starting point for the new plan to aid
and speed up the plan optimisation process. Nwankwo
et al. [5] developed a knowledge based planning
algorithm that predicts the 3D dose distribution of an
OAR based upon its proximity to the OAR.
This paper describes the implementation of the
method developed by Moore et al. at the Worcestershire
Oncology Centre using the RayStation treatment plan-
ning system. It establishes a locally relevant predictive
model, validates its use in removing sub-optimal plans
and describes the impact of a controlled implementa-
tion. The Moore et al. model was chosen from the afore-
mentioned knowledge based planning solutions in the
literature due to the demonstrated potential for signifi-
cant clinical benefit whilst being relatively simple to im-
plement locally within the RayStation scripting interface.
Methods
This work has focussed upon external beam radiother-
apy of prostate patients at the Worcestershire Oncology
Centre (WOC) which is delivered according to the
CHHiP trial (CRUK/06/016) protocol. Patients are
planned with three concentric target volumes PTV3,
PTV2 and PTV1 prescribed 74Gy, 71Gy and 59.2Gy in
37 fractions respectively. Patients are separated into two
categories depending upon whether they present a high
or low risk of seminal-vesicle involvement. For high risk
(HR) patients PTV3 is equal to the prostate outline plus
a 5 mm isotropic margin (0 mm posteriorly), PTV2 is
the prostate and seminal vesicles combined plus a
10 mm isotropic margin (5 mm posteriorly) and PTV1
is the prostate and seminal vesicles combined plus a
10 mm isotropic margin. For low risk (LR) patients the
PTV structures are grown in the same manner as
described for HR however PTV2 is grown from the
prostate outline only.
Method A: forming a local knowledge base for prostate
planning
A script (henceforth referred to as the data-mining script)
was produced within the RayStation scripting interface to
interrogate a historic cohort of 97 prostate patients
planned and treated between February 2015 and February
2016 at WOC. All patients were treated with single arc
6MV photon VMAT plans, received no nodal irradiation
and had no artificial hip implants. The patients were
distributed evenly between the disease-risk sub-cohorts
with 49 patients designated as HR and 48 as LR.
For each patient the script extracted or calculated a
variety of data for analysis including: ROI volumes,
PTV-OAR overlap volumes, OAR mean doses (including
average rectum dose), DVH data for PTV and OAR
structures and plan quality/complexity metrics such as
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conformity index and total plan MU. In this work the
conformity index (CI) is defined as the ratio between the
volume of a target covered by a user specified isodose
and the total volume covered by the isodose.
Using the data extracted by the script, the ratio of the
average rectum dose (Dmean
rectum) to the primary prescrip-
tion dose (DPx) of 74Gy to PTV3, and the ratio of the
volume of rectum overlapping PTV1 (Vovr) to the overall
volume of the rectum (Vrec) was calculated for each
patient. To assess whether the trend between average
rectum dose and geometric OAR-PTV overlap reported
by Moore et al. was evident in the historic cohort Dmean
rec-
tum/DPx was plotted against Vovr/Vrec. The coefficients in
Equation 1 were adjusted to provide an approximate fit
the Moore et al. mathematical model to the local plot of
Dmean
rectum/DPx versus Vovr/Vrec. This was done twice: firstly
so that the mathematical model fit along the lower
bound of the local data representing the “optimal
average rectum dose” (OARD) achieved in the historic
cohort and secondly so that the mathematical model fit
through the middle of the historic cohort representing
the “median average rectum dose” (MARD).
Method B: validation of local model
If the OARD is a valid metric for identifying plans with
“sub-optimal” rectal sparing (i.e. Dmean
rectum > > OARD) it is
hypothesised that re-planning those patients would yield
an improvement in rectal sparing. Similarly, re-planning
those patients with “optimal” original clinical plan (i.e.
Dmean
rectum ≈ OARD) would yield little or no change in rectal
sparing.
Moore et al. defined the relative model excess, δ, to
quantify the difference in achieve mean rectal dose com-
pared to the predicted value (Dpred) as follows,
δ ¼ Dmean− DPred
Dpred
ð2Þ
This metric was chosen as it is insensitive to absolute
values in dose or overlap volume allowing comparison of
plans across different sites and prescriptions [1]. A plan-
ning study was devised to test whether the OARD and
MARD models could be used to assess if a plan was “op-
timal” (compared to the historical knowledge base) in
terms of rectal sparing utilising the metric δ.
For each patient in the historic cohort δ was calculated
using Equation 2 where Dpred was calculated using the
local OARD model introduced in Method A: Forming a
Local Knowledge Base for Prostate Planning. Ten pa-
tients were selected from the cohort; five patients with a
high δ-value (where Dmean
rectum > > OARD and implying that
the original clinical plans were “sub-optimal” in terms of
rectum dose) and five patients with δ ≈ 0 (Dmean
rectum ≈
OARD) implying that the original clinical plans were
close to the best achieved in the historical cohort). Prior
to the study the ten plans were reviewed by an inde-
pendent experienced planner to check that there were
no mitigating circumstances explaining why each plan
might exhibit a high rectum dose.
The patients were anonymised and four experienced
planners were each asked to produce a new plan for
each patient. The planners were provided with additional
planning goals to ensure that the new plans maintained
similar levels of PTV coverage and non-rectum OAR
sparing compared to the original clinical plans. These
additional goals included D99 targets for PTV1, PTV2,
and PTV3, mean dose and D10 targets for the bladder
and low dose conformity indices. Additionally, planners
were asked to achieve rectal sparing where they felt it
was achievable but were not informed as to which plans
were predicted to have scope for rectal dose reduction.
The relative model excess, δ was calculated for each
replan and the average δ across the four planners was
calculated for each patient and compared to δ for the
original clinical plan to assess if the plan average rectal
dose had improved.
Method C: implementation of local knowledge based
planning tool
A RayStation script, henceforth referred to as the know-
ledge based planning (KBP) script, was developed for
clinical implementation utilising the mathematical
models for predicting OARD and MARD established in
Method A: Forming a Local Knowledge Base for Pros-
tate Planning. Upon execution the KBP script performs
the following tasks:
 Determines the volume of the rectum ROI that
overlaps the PTV1 target and calculates Vovr/Vrec.
 Calculates the corresponding MARD and OARD
using the mathematical models established in
Method A: Forming a Local Knowledge Base for
Prostate Planning.
 Displays the prescription dose, fractionation, Vovr/
Vrec, current plan average rectum dose, MARD and
OARD in a graphical user interface.
Once the user has acknowledged the results graphical user
interface (GUI) a message box is created advising the user
that the current average rectum dose is either not-
acceptable, acceptable or “optimal” depending upon whether
Dmean
rectum >MARD, MARD> Dmean
rectum >OARD or Dmean
rectum <=
OARD respectively . Initial preliminary testing suggested
that using the KBP script could lead to greater rectum spar-
ing at the cost of an increase in plan MU, a slight reduction
in PTV1 coverage (but still within the clinical goal) and a re-
duction in low dose conformity with an associated increase
in femoral head dose (but again still within the clinical goal).
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Prior to implementing the KBP script clinically the benefits
and potential costs were raised with local clinicians. The
clinicians were willing to accept the aforementioned costs in
order to obtain reductions in average rectum dose.
The KBP script was implemented clinically, with plan-
ners asked to ensure that the current plan average rectum
dose was at least lower than the MARD and preferably
equal to or lower than the OARD presented in the KBP
script GUI. The data extracted from the data-mining
script (see Method A: Forming a Local Knowledge Base
for Prostate Planning) were used to determine values for
PTV3 coverage, low dose conformity index and total plan
MU that were routinely achieved in the historical cohort
and were desirable in all future plans. As a precaution,
these values were added as additional clinical goals to be
met during the planning process in order to reduce the
risk of the KBP script generating unforeseen changes in
practice or plan quality.
Results
Results A: forming a local knowledge base for prostate
planning
Figure 1 displays (Dmean
rectum/DPx) plotted against (Vovr/Vrec)
for the WOC prostate historical cohort. The data pre-
sents a clear trend with average rectum dose increasing
as the fractional overlap of the rectum and PTV1 in-
creases which is consistent with the trend observed by
Moore et al. The data displays no significant variation
between the HR (solid data points) and LR (hollow data
points) patient cohorts and throughout the remainder of
this report the stratification according to disease risk is
ignored (i.e. the data is treated as a single cohort).
The dotted curve is the mathematical fit reported by
Moore et al. The solid curve represents the optimal
(OARD) fit to the entire historical cohort described by
equation 1 using coefficients A = 0.33, B = 0.5 and C =
−2.3. The dashed curve represents the median (MARD)
fit to the entire historical cohort described by equation 1
using coefficients A = 0.38, B = 0.5 and C = −2.3.
Results B: preliminary testing of local model
The average change in δ was −0.08 (range −0.12 to
−0.01) for the high-δclin cohort and −0.02 (range −0.06
to 0.00) for the low-δclin cohort. Applying a single-tailed
paired t-test, the high-δclin cohort exhibits a statistically
significant reduction in δ between the original clinical
plans and the average of the replans (p = 0.009). This in-
dicates that when re-planned these patients observed an
overall reduction in mean rectum dose relative to the
original clinical plan so that the planned average dose
was closer to the OARD prediction. In contrast, the low-
δclin cohort do not exhibit a statistically significant
change in δ (p = 0.201). This suggests that when re-
planned these patients observed only a very small
change in mean rectum dose compared to the original
clinical plan.
Whilst the preliminary study only contained five
patients in each cohort (limiting its statistical power)
overall the results support the hypothesis that the OARD
can be used to identify plans which are “sub-optimal” in
terms of average rectum dose. Despite the limited
Fig. 1 Average dose to the rectum normalised to the prescription dose (Dmean
rectum/DPx) plotted against the volume of the rectum overlapping PTV1
expressed as a fraction of total rectum volume (Vovr/Vrec). Data is plotted for high risk (solid) and low risk (open) patients. The dashed and solid
curves represent the local MARD and OARD models respectively whereas the dotted curve represents the model of Moore et al. [1]
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statistical power of this test, it provided sufficient
confidence to proceed with the clinical implementation
described in method C. The dose to the femoral heads
was not actively controlled during the study however there
was no systematic increase in femoral head D50 observed
when comparing the replans to the original clinical plans.
Results C: implementation of local knowledge based
planning tool
Figure 2 displays Dmean
rectum/DPx plotted against Vovr/Vrec
for the historic patient cohort planned pre-KBP (open
diamonds) and the first 33 patients post-KBP script im-
plementation (filled-diamonds). All 33 plans produced
post-script implementation met all clinical goals and
were approved as clinically acceptable following the rou-
tine local plan checking and approval processes. The
solid and dashed green lines in Fig. 2 represent the pre-
dicted OARD and MARD respectively for the historical
cohort as introduced in Method A: Forming a Local
Knowledge Base for Prostate Planning.
For the historical cohort (pre-KBP script implementa-
tion) the patients are distributed evenly around the
MARD curve and the mean δ was 0.11 ± 0.08. Post-
implementation of the KBP script the average rectum
dose is reduced substantially so that patients are distrib-
uted around the OARD curve and every plan exhibits Dmean-
rectum < MARD. Post-script implementation the mean δ
was −0.03 ± 0.06.
Table 1 displays mean values for a variety of plan statistics
for the patient plans produced pre- and post-KBP script im-
plementation, and p-values (calculated using a two-sample,
Fig. 2 Average dose to the rectum normalised to the prescription dose (Dmean
rectum/DPx) plotted against the volume of the rectum overlapping PTV1
expressed as a fraction of total rectum volume (Vovr/Vrec). Data is plotted for 33 patients planned post KBP script implementation (solid) and for
the historical cohort (open). The dashed and solid curves represent the local MARD and OARD models respectively
Table 1 Population-averaged plan statistics (standard deviation in
parentheses) for the patients planned pre- and post- KBP script
implementation
Metric Pre Post P-value
PTV3 D99 (Gy) 72.4 (0.5) 72.4 (0.4) 0.748
PTV3 D1 (Gy) 75.1 (0.6) 75.1 (0.4) 0.904
PTV2 D99 (Gy) 67.6 (0.3) 67.7 (0.3) 0.471
PTV1 D99 (Gy) 59.3 (2.9) 59.7 (2.0) 0.351
Total MU 428 (70) 463 (73) 0.018
Av Bladder dose (Gy) 23.2 (8.8) 22.3 (7.8) 0.580
Av Rectum dose (Gy) 41.6 (4.2) 36.0 (4.1) <0.001
Av bowel dose (Gy) 23.7 (19.9) 14.1 (14.8) 0.289
LFemH D50 (Gy) 21.7 (7.1) 26.3 (5.6) <0.001
RFemH D50 (Gy) 21.6 (7.3) 27.2 (7.1) <0.001
CI (56.2Gy to PTV1) 0.69 (0.06) 0.65 (0.04) <0.001
CI (40.0Gy to PTV1) 0.37 (0.04) 0.34 (0.03) <0.001
δ 0.11 (0.08) −0.02 (0.06) <0.001
Rectum V30/Vrec 0.71 (0.07) 0.54 (0.10) <0.001
Rectum V40/Vrec 0.54 (0.11) 0.38 (0.01) <0.001
Rectum V50/Vrec 0.37 (0.11) 0.28 (0.08) <0.001
Rectum V60/Vrec 0.21 (0.10) 0.18 (0.06) 0.110
Rectum V65/Vrec 0.13 (0.08) 0.13 (0.05) 0.787
Rectum V70/Vrec 0.07 (0.04) 0.07 (0.03) 0.457
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two-tailed t-test assuming unequal variances) indicating
whether the difference in the distribution of plan statistics
pre- and post- script implementation are statistically signifi-
cant (assuming a significance level of p < 0.05).
Discussion
All plans produced post-script implementation met all
clinical goals and were considered clinically acceptable
following the local plan checking and approval process.
Introduction of the KBP script reduced the population-
averaged mean rectum dose from 41.6Gy in the historic
cohort to 36.0Gy in the post-KBP script implementation
cohort (see Table 1).
A more robust method for comparison that considers
variation in dose with PTV-rectum overlap is to examine
the change in the curve in Fig. 2 following implementa-
tion of the KBP tool. A new MARD curve fitted to the
post-KBP data was found to have Dmean
rectum/DPx on average
0.05 lower, corresponding to a reduction in Drec = 3.7Gy
for DPx = 74Gy. This change corresponds to the data
being approximately equivalent to the OARD curve
established pre-KBP implementation, suggesting that the
post-implementation median level of rectal sparing has
now converged on the previously optimal practice.
Similarly, individual cases in the historical cohort are
positioned well above the original MARD curve imply-
ing that rectum dose was sub-optimal for these patients,
but comparison of the curves describing the outlying
plans before and after implementation of the script
showed that Dmean
rectum/DPx reduced by an average 0.07 cor-
responding to a change in Drec = 5.2Gy for DPx = 74Gy.
This means that post-implementation the least optimal
plans are now of similar quality to the median levels
achieved prior to implementation, which might be
expected as the planners were always asked to obtain
the median expected value or better.
From Fig. 1 it can be seen that whilst the general trend
reported by Moore et al. (i.e. increased overlap results in
increased OAR dose) is observed in the historical cohort
the local data is much shallower than the Moore et al.
model. This suggests that historically local patients exhi-
biting a small overlap between rectum and PTV1 were
being planned with doses only moderately lower than
patients with much larger overlap volumes suggesting
that the planner stopped optimising the plan too soon in
these instances. Post script implementation (see Fig. 2)
average rectum doses are reduced overall but for a few
patients exhibiting lower overlap volumes (Vovr/Vrec <
=0.2) the reduction in average rectum dose was more
pronounced. If a new curve was drawn to represent the
optimum average rectum dose post-script implementa-
tion the new curve would be much steeper and closer to
that proposed by Moore et al. This indicates that intro-
ducing the script has increased the steepness of the local
data by encouraging planners to continue optimising
plans where further gains are most achievable. This rep-
resents a potentially significant gain in plan quality from
this simple application however further data is required
to confirm the steeper trend post-script implementation.
In order to assess the impact of this tool on clinical
practice the data mining script was used to extract plan
statistics from the post-KBP script implementation
cohort which were compared to the same results from
the historical cohort (see Table 1). The difference
between D99 and D1 for PTV3, D99 for PTV2 and D99
for PTV1 before and after implementation of the script
was less than 0.5Gy. This change is not statistically sig-
nificant (applying a t-test with 0.05 significance level)
implying that target coverage has been unaffected by the
KBP script. The average plan MU increased post-script
implementation from 427MU to 466MU indicating that
the script instigated a statistically significant increase in
plan complexity. This result was predicted as improving
rectal sparing whilst maintaining other aspects of plan
quality can only be achieved through greater plan modu-
lation. Whilst statistically significant this increase in plan
MU is modest and significantly below the upper thresh-
old of 600MU applied as part of this study. The average
mean bladder dose reduced slightly by 0.9Gy following
script implementation. This small reduction in dose is
not statistically significant but confirms that the script
induced increase in rectal sparing has not generated an
unforeseen increase in bladder dose. Average bowel dose
has decreased by 3.8Gy post-script implementation. This
decrease is not statistically significant but indicates that
the script has introduced a desirable trend for lower
bowel doses. This is likely a consequence of increased
dose conformity at the posterior surface of the PTV
structures created whilst attempting to spare the rectum.
Whilst the dose to the aforementioned OAR structures
has remained stable or reduced post-script implementa-
tion the dose to both femoral heads has increased. This
is a direct result of the script encouraging planners to
push dose from the rectum OAR resulting in lateral low
dose spread towards the femoral heads. The increase in
lateral dose spread is also observed as a statistically sig-
nificant reduction in CI (see Table 1). Both the increase
in femoral head dose and lateral dose spread were
foreseen prior to script implementation and the risk ac-
cepted by local clinicians and controlled via plan quality
constraints. Furthermore the average femoral head dose
and CI values are well within accepted clinical tolerances
and are therefore of low concern.
Whilst the change in femoral head dose is not of
clinical concern, since it tends to fall easily well within
clinical tolerance, it does raise a question about the
nature of the plan improvements induced by the KBP
tool. The pre-implementation study revealed no
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apparent change in femoral head dose compared to ori-
ginal clinical plan when re-planned for both the “sub-op-
timal” and “optimal” cohorts however the sub-optimal
cohort demonstrated a benefit in rectum dose. This im-
plies that the KBP metric was able to identify plans that
were legitimately sub-optimal (i.e. not on the pareto op-
timal front). However, when actively employing the tool
to guide planners an increase in femoral head dose is
observed relative to the pre-KBP population. This per-
haps indicates that, for some plans at least, the KBP tool
has induced a shift along the pareto front rather than
shifting a sub-optimal plan onto the pareto front. This
may especially be true for those patients where the mean
rectum dose is significantly below OARD. RayStation
MCO module allows users to investigate the trade-offs
whilst moving across the pareto front and should enable
the production of pareto optimal plans [9, 10]. This ap-
proach is different to KBP planning in that it does not
directly rely upon previous local knowledge to produce
optimal plans. MCO planning, however, does require
user specified trade-off optimisation functions and con-
straints in order to produce an initial collection of pa-
reto plans. These plans are then examined and explored
by the user in order to produce the final clinical plan.
The quality of the final optimal plan is therefore heavily
reliant upon the initial user-specified trade-off functions.
It is therefore important that thorough commissioning
work is performed to ascertain the most suitable initial
set of trade-off functions for a given clinical site in in
order to ensure that a truly pareto optimal final plan is
produced. The MCO planning module has not been
commissioned for clinical use locally however the KBP
tool presented in this work could be used to assess
whether plans generated by MCO are, in terms of aver-
age rectum dose, comparable to (or better than) those
automated manually acting as a valuable aid during the
commissioning process. The KBP tool presented here
can therefore be used as an alternative to MCO or to
compliment MCO to QA final plan quality.
The reduction in population-averaged mean rectum
dose induced by implementation of the KBP script is pri-
marily achieved via a reduction in the amount of moder-
ate to low-dose (i.e. <= 50Gy) delivered to the rectum.
This is illustrated in Table 1 where the average V30, V40
and V50 (expressed as a fraction of total rectum volume)
are statistically significantly lower for the population of
plans produced post-script implementation compared to
the historical cohort. In contrast, the average V60, V65
and V70 are approximately the same for the post-script
and historical cohorts. This result is to be expected as
the volume of rectum receiving the highest doses will be
the region overlapping the PTV and therefore achievable
dose reduction to this region is more limited without
compromising target coverage. One possible concern to
driving the optimisation of a plan using the KBP tool is
that we may increase dose elsewhere, particularly around
the rectum. However, the dose within 1 cm of the rec-
tum did not increase as a function of δ-values, suggest-
ing that plans optimised using the KBP tool remain
robust to intrafractional rectum changes.
Reports in the literature are mixed about the clinical
benefits of reducing moderate-low dose exposure to the
rectum. The QUANTEC review concluded that high
dose limits (> = 60Gy) were of greater significance in
terms of rectal toxicity than lower doses (<60Gy) [11].
This conclusion is supported by Fiorino et al. [12],
Tucker et al. [13] and Michalski et al. [14] whose studies
found correlations between grade 2 rectal toxicity and
high dose volumes only. However there also exist a sig-
nificant number of studies reporting that the extent of
low/intermediate dose rectum exposure correlates with
rectal toxicity. For example, Buettner et al. [15] investi-
gated the shape of the dose distribution across the rec-
tum and the correlation with toxicity reporting a
correlation between rectal bleeding and doses between
40-60Gy. Gulliford et al. [16] reported a reduction in the
incidence of moderate/severe rectal toxicity with dose
reduction across the whole DVH concluding that lower
doses are of clinical importance. Although investigating
hypofractionated treatments, Kim et al. [17] reported a
strong correlation between grade 2+ delayed rectal
toxicity and the percentage of rectal wall circumference
receiving low dose. There is therefore evidence to sug-
gest that the reduction in low/moderate dose exposure
to the rectum, driven by the introduction of the KBP
script, has a real clinical benefit to the patient in terms
of reduced risk of rectal toxicity. Follow-up work from
this study will investigate the feasibility of making more
limited gains by optimising the dose in the rectal-PTV
overlap region.
Conclusions
RayStation has been used successfully to guide planners
on the expected value of a key plan quality metric, lead-
ing to significant reduction in population-averaged mean
rectal dose, which may translate into reduced toxicity
risk for patients. A shared knowledge base with other
RayStation users would be desirable to allow centres to
benchmark local plan quality against that achieved
elsewhere and drive overall improvement.
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